SCHEMBL23488562

SCHEMBL23488562

COc1c(C(=O)O[C@H]2[C@@H](OC)O[C@H](CO)[C@@H](O)[C@@H]2O)ccc(OCc2ccccc2)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 6/20 0.47
LGALS9 O00182 1/20 0.47
LGALS1 P09382 1/20 0.47
LGALS7; LGALS7B P47929 1/20 0.47
LGALS8 O00214 3/20 0.47
POLB P06746 1/20 0.42
LGALS4 P56470 4/20 0.42
SLC5A1 P13866 2/20 0.38
SLC5A2 P31639 2/20 0.38
SLC6A2 P23975 1/20 0.38
EPHX2 P34913 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488625 0.87 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488453 0.87 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488691 0.84 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488683 0.82 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488497 0.82 LGALS8 (0.48) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488634 0.82 LGALS3 (0.49) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488694 0.82 LGALS8 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488142 0.82 LGALS8 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488619 0.82 LGALS3 (0.47) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8
SCHEMBL23488494 0.81 NPC1 (0.50) LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 LGALS3 156/4885LGALS9 106/4885LGALS1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.